地塞米松对住院糖尿病合并COVID-19患者的疗效:一项回顾性队列研究
该回顾性队列研究分析了约翰霍普金斯卫生系统5家医院2020年3月3日至2022年6月25日收治的糖尿病合并COVID-19住院患者,经倾向性评分匹配后每组529例,比较接受与未接受地塞米松治疗者的结局。结果显示两组28天内生存率及临床改善时间均无显著差异,糖尿病酮症酸中毒和高渗高血糖状态发生率也无差异。
要点
- 糖尿病合并COVID-19住院患者中,地塞米松组与对照组28天生存率无显著差异。
- 两组28天临床改善时间无显著差异。
- 两组糖尿病酮症酸中毒或高渗高血糖状态发生率无差异。
核心结论
- 地塞米松治疗未显著改善糖尿病合并COVID-19感染患者的生存率或临床改善时间,需进一步前瞻性研究确认这些发现并确定潜在机制。
研究设计与样本
- 回顾性研究分析约翰霍普金斯卫生系统5家医院2020年3月3日至2022年6月25日收集的数据。
- 对接受地塞米松的糖尿病住院患者与未接受者(对照组)进行倾向性评分匹配,采用Cox比例风险回归模型比较结局。
- 10,329例COVID-19住院患者中3,679例有糖尿病,2,361例符合纳入标准,倾向性评分匹配后每组529例进行分析。
主要发现
- 地塞米松组与对照组在0至6天和7至28天期间的生存率无显著差异。
- 地塞米松组与对照组28天临床改善时间无显著差异。
- 两组糖尿病酮症酸中毒或高渗高血糖状态发生率无差异。
关键数值与推荐
- 主要结局为28天内死亡时间。
- 次要结局为临床改善时间。
- 其他结局包括高血糖急症发生率及按临床严重程度分层的亚组分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with diabetes have higher mortality from COVID-19 compared to the general population. Dexamethasone, a potent glucocorticoid used for moderate to severe COVID-19, can worsen hyperglycemia in patients with diabetes, potentially leading to worse outcomes. The efficacy and safety of use of dexamethasone for COVID-19 in patients with diabetes needs further evaluation. OBJECTIVE: The study aimed to assess the efficacy and safety of dexamethasone in patients with diabetes hospitalized for COVID-19 infection. DESIGN: This retrospective study analyzed data from 5 hospitals in the Johns Hopkins Health System collected between March 3, 2020, and June 25, 2022. Propensity score matching was applied to a cohort of patients with diabetes who received dexamethasone and those who did not (controls), and outcomes were compared using Cox proportional hazards regression models. OUTCOMES: The primary outcome was time to death within 28 days. The secondary outcome was time to clinical improvement. Additional outcomes included the incidence of hyperglycemic emergencies and subgroup analysis of primary outcomes by clinical severity. RESULTS: Out of 10,329 patients admitted for COVID-19, 3679 had diabetes, and 2361 met the inclusion criteria. After propensity score matching, 529 patients were analyzed in each group. Survival rates between the dexamethasone and control groups during the 0- to 6-day and 7- to 28-day periods and time to clinical improvement at 28 days did not differ significantly. There was no difference in the incidence of diabetic ketoacidosis or hyperosmolar hyperglycemic state between the groups. CONCLUSION: Dexamethasone treatment did not significantly improve survival or time to clinical improvement in patients with diabetes and COVID-19 infection. Further prospective studies are needed to confirm these findings and determine potential mechanisms.
引用
- Bhat SZ, Wu J, Perin J, et al. Effectiveness of Dexamethasone for COVID-19 in Hospitalized Patients With Diabetes: A Retrospective Cohort Study. J Clin Endocrinol Metab. 2025. PMID: 39418352. doi:10.1210/clinem/dgae734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。